Picture of SGS SA logo

SGSN — SGS SA News Story

0.000.00%
ch flag iconLast trade - 00:00
IndustrialsConservativeLarge CapHigh Flyer

Brief: Biontech And Oncoc4 Announce Clinically Meaningful Overall Survival Benefit For Lung Cancer Drug

Dec 8 (Reuters) - Biontech22UAy.DE said on Saturday:

BIONTECH AND ONCOC4 ANNOUNCE CLINICALLY MEANINGFUL OVERALL SURVIVAL BENEFIT FOR SELECTIVE TREG MODULATOR GOTISTOBART IN PATIENTS WITH PREVIOUSLY TREATED SQUAMOUS NON-SMALL CELL LUNG CANCER

GOTISTOBART SHOWED A REDUCTION IN THE RISK OF DEATH BY MORE THAN HALF COMPARED TO STANDARD OF CARE CHEMOTHERAPY

GOTISTOBART WAS GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (“FDA”)

GRADE ≥3 TREATMENT-RELATED ADVERSE EVENTS (“AES”) WERE REPORTED IN 19/45 (42.2%) PATIENTS IN THE GOTISTOBART TREATMENT ARM VERSUS 20/41 (48.8%) PATIENTS IN DOCETAXEL TREATMENT ARM

 Further company coverage: [22UAy.DE]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on SGS SA

See all news